Sweden Mahmood takes up CEO position at Acarix - Investors in Healthcare
| ACARIX Stock | SEK 0.31 0.01 3.33% |
About 55% of Acarix AS's investors are presently thinking to get in. The analysis of current outlook of investing in Acarix AS suggests that some traders are interested regarding Acarix AS's prospects. The current market sentiment, together with Acarix AS's historical and current headlines, can help investors time the market. In addition, many technical investors use Acarix AS stock news signals to limit their universe of possible portfolio assets.
Acarix |
Sweden Mahmood takes up CEO position at Acarix Investors in Healthcare
Read at news.google.com
 |
Acarix AS Fundamental Analysis
We analyze Acarix AS's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Acarix AS using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Acarix AS based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Ratio
Current Ratio Comparative Analysis
Acarix AS is currently under evaluation in current ratio category among its peers. Current Ratio is calculated by dividing the Current Assets of a company by its Current Liabilities. It measures whether or not a company has enough cash or liquid assets to pay its current liability over the next fiscal year. The ratio is regarded as a test of liquidity for a company.
Acarix AS Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Acarix AS stock to make a market-neutral strategy. Peer analysis of Acarix AS could also be used in its relative valuation, which is a method of valuing Acarix AS by comparing valuation metrics with similar companies.
Peers
Acarix AS Related Equities
| BIOVIC-B | Biovica International | 6.44 | ||||
| SANION | Saniona AB | 4.73 | ||||
| CANTA | Cantargia | 1.63 | ||||
| EXPRS2 | ExpreS2ion Biotech | 1.99 |
Complementary Tools for Acarix Stock analysis
When running Acarix AS's price analysis, check to measure Acarix AS's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acarix AS is operating at the current time. Most of Acarix AS's value examination focuses on studying past and present price action to predict the probability of Acarix AS's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acarix AS's price. Additionally, you may evaluate how the addition of Acarix AS to your portfolios can decrease your overall portfolio volatility.
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| FinTech Suite Use AI to screen and filter profitable investment opportunities |